PegBio Co., Ltd.
🇭🇰Hong Kong, China
- Country
- 🇭🇰Hong Kong, China
- Ownership
- Holding
- Established
- 2008-05-13
- Employees
- 51
- Market Cap
- -
- Website
- http://www.pegbio.com
Clinical Trials
15
Active:1
Completed:11
Trial Phases
3 Phases
Phase 1:9
Phase 2:2
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Phase 1
9 (60.0%)Phase 3
4 (26.7%)Phase 2
2 (13.3%)A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06350812
- Locations
- 🇨🇳
The Third XIANGYA Hospital of Central South University, Changsha, Hunan, China
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects.
- First Posted Date
- 2023-11-27
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06147544
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05328843
- Locations
- 🇨🇳
Jia Miao, Chengdu, Sichuan, China
Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients With Poor Glycemic Control Via Metformin Hydrochloride Monotherapy
Phase 3
Not yet recruiting
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 546
- Registration Number
- NCT05326490
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus
Phase 3
Recruiting
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- PegBio Co., Ltd.
- Target Recruit Count
- 672
- Registration Number
- NCT05102149
- Locations
- 🇨🇳
The Second People's Hospital of Hefei, Hefei, Anhui, China
🇨🇳Lu'an People's Hospital, Lu'an, Anhui, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- Next
News
No news found